Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances

Faria, Maria João; Lopes, Carla Martins; Neves, José das; Lúcio, Marlene

doi:10.3390/pharmaceutics13081294

Cited by 15 publications

(9 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, there is supportive evidence suggesting that the pathogenesis of HIV-associated dementia is likely attributed to indirect effects of HIV infection on the brain, possibly mediated through the actions of macrophages and microglia [42]. Faria et al [43] proposed the utilization of lipid nanocarriers for anti-HIV therapeutics to enhance penetration into HIV reservoir sites and surmount biological barriers such as BBB upon administration. Nanocarriers, when coated with specific surface stabilizers, offer potential utility in achieving elevated drug concentrations in the brain during CNS administration.…”

Section: Discussionmentioning

confidence: 99%

The Influence of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial Activity, Lipid Content, and Fatty-Acid-Binding Protein Levels in Microglial HMC3 Cells

Lipke,

Kubis-Kubiak,

Piwowar

2023

Pharmaceuticals

View full text Add to dashboard Cite

Despite the availability of a wide range of preventive measures and comprehensive treatment options following infection, the development of acquired immunodeficiency syndrome (AIDS) remains a persistent challenge. Nucleoside reverse transcriptase inhibitors (NRTIs) represent the most commonly utilized therapeutic approach, despite being on the pharmaceutical market for nearly four decades. During this time, a spectrum of side effects ranging from mild discomfort and hypersensitivity reactions to the more prevalent nephrotoxicity and hepatotoxicity has been documented. In light of these considerations, our study aimed to investigate the impacts of two NRTIs, lamivudine and zidovudine, on lipid metabolism in HMC3 microglial cells. Our findings revealed statistically significant reductions in the ATP levels (nearly 8%) and increased mitochondrial superoxide levels (around 10%) after 24 h of treatment with the maximum therapeutic concentration of zidovudine compared to the untreated microglial cells. Furthermore, the concentrations of fatty-acid-binding proteins 4 and 5 were significantly lower (approximately 40%) in the microglial cells that were exposed to NRTIs than in the untreated cells. Notably, the total lipid concentration within the microglial cells markedly increased following NRTI administration with a 13% rise after treatment with 10 µM lamivudine and a remarkable 70% surge following the administration of 6 µM zidovudine. These results suggest that the prolonged administration of NRTIs may potentially lead to lipid accumulation, posing a significant risk to the delicate homeostasis of the neuronal system and potentially triggering a pro-inflammatory response in microglial cells.

show abstract

Section: Discussionmentioning

confidence: 99%

The Influence of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial Activity, Lipid Content, and Fatty-Acid-Binding Protein Levels in Microglial HMC3 Cells

Lipke,

Kubis-Kubiak,

Piwowar

2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…LNPs belong to the organic nano-system and have hydrophilic parts exposed to the surrounding aqueous solvent as well as hydrophobic parts facing each other to form a supramolecular structure [ 124 ]. LNPs are particularly attractive for biomedical applications, owing to their enhanced lipid-specific biocompatibility.…”

Section: Np Delivery—a Platform Ensuring the Efficacy And Stability O...mentioning

confidence: 99%

Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract

Zhang

Almazi

Ong

et al. 2022

IJMS

View full text Add to dashboard Cite

Since December 2019, a pandemic of COVID-19 disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread across the globe. At present, the Food and Drug Administration (FDA) has issued emergency approval for the use of some antiviral drugs. However, these drugs still have limitations in the specific treatment of COVID-19, and as such, new treatment strategies urgently need to be developed. RNA-interference-based gene therapy provides a tractable target for antiviral treatment. Ensuring cell-specific targeted delivery is important to the success of gene therapy. The use of nanoparticles (NPs) as carriers for the delivery of small interfering RNA (siRNAs) to specific tissues or organs of the human body could play a crucial role in the specific therapy of severe respiratory infections, such as COVID-19. In this review, we describe a variety of novel nanocarriers, such as lipid NPs, star polymer NPs, and glycogen NPs, and summarize the pre-clinical/clinical progress of these nanoparticle platforms in siRNA delivery. We also discuss the application of various NP-capsulated siRNA as therapeutics for SARS-CoV-2 infection, the challenges with targeting these therapeutics to local delivery in the lung, and various inhalation devices used for therapeutic administration. We also discuss currently available animal models that are used for preclinical assessment of RNA-interference-based gene therapy. Advances in this field have the potential for antiviral treatments of COVID-19 disease and could be adapted to treat a range of respiratory diseases.

show abstract

“…A study has shown that SLNs improved the pharmacokinetic parameters of the HIV protease inhibitor atazanavir [ 71 ]. A 2021 study discussed the importance of using lipid-based nanocarriers to deliver anti-retroviral drug molecules, as well as the specificity of the drug molecules delivered to the target [ 72 ]. A 2019 study reported the efficacy of acyclovir solid lipid nanoparticles that resulted in the sustained release of acyclovir achieved as a single dose [ 53 ].…”

Section: Miscellaneousmentioning

confidence: 99%

Perspectives and Prospective on Solid Lipid Nanoparticles as Drug Delivery Systems

Madkhali

2022

Molecules

View full text Add to dashboard Cite

Combating multiple drug resistance necessitates the delivery of drug molecules at the cellular level. Novel drug delivery formulations have made it possible to improve the therapeutic effects of drugs and have opened up new possibilities for research. Solid lipid nanoparticles (SLNs), a class of colloidal drug carriers made of lipids, have emerged as potentially effective drug delivery systems. The use of SLNs is associated with numerous advantages such as low toxicity, high bioavailability of drugs, versatility in the incorporation of hydrophilic and lipophilic drugs, and the potential for production of large quantities of the carrier systems. The SLNs and nanostructured lipid carriers (NLCs) are the two most frequently used types of nanoparticles. These types of nanoparticles can be adjusted to deliver medications in specific dosages to specific tissues, while minimizing leakage and binding to non-target tissues.

show abstract

Lipid Nanocarriers for Anti-HIV Therapeutics: A Focus on Physicochemical Properties and Biotechnological Advances

Cited by 15 publications

References 158 publications

The Influence of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial Activity, Lipid Content, and Fatty-Acid-Binding Protein Levels in Microglial HMC3 Cells

The Influence of Nucleoside Reverse Transcriptase Inhibitors on Mitochondrial Activity, Lipid Content, and Fatty-Acid-Binding Protein Levels in Microglial HMC3 Cells

Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract

Perspectives and Prospective on Solid Lipid Nanoparticles as Drug Delivery Systems

Contact Info

Product

Resources

About